Avidity Biosciences to Participate in Upcoming Investor Conference

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA) said management will participate in a panel at the Chardan 9th Annual Genetic Medicines Conference in New York on Oct 21, 2025 at 11:00 a.m. PT / 2:00 p.m. ET. A live webcast, event details, and an archived replay will be available on the company's Investors > Events and Presentations webpage.

This is a scheduled investor-conference panel appearance; no financial or clinical data, guidance, or transactions were announced.

SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a panel discussion at the following investor conference:

• Chardan 9^th Annual Genetic Medicines Conference, New York, NY
  Tuesday, October 21, 2025, at 11:00 a.m. PT / 2:00 p.m. ET

A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity  
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com

Media Contact:
Kristina Coppola
(619) 837-5016
media@aviditybio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302585667.html

SOURCE Avidity Biosciences, Inc.

FAQ

When will Avidity Biosciences (RNA) present at the Chardan Genetic Medicines Conference?

Avidity management will participate on Oct 21, 2025 at 11:00 a.m. PT / 2:00 p.m. ET.

How can investors watch Avidity (RNA) at the Oct 21, 2025 conference?

A live webcast and an archived replay will be available on Avidity's Investors > Events and Presentations webpage.

What topics will Avidity Biosciences (RNA) cover at the Chardan conference on Oct 21, 2025?

The announcement states management will join a panel; no specific presentation topics or new data were disclosed.

Where is the Chardan 9th Annual Genetic Medicines Conference taking place for Avidity (RNA)?

The conference is in New York, NY; Avidity's participation is a panel session on Oct 21, 2025.

Will Avidity (RNA) publish materials or a replay after the Oct 21, 2025 panel?

Yes; an archived replay and up-to-date event details will be posted on the company's investor events and presentations page.

Does the Oct 21, 2025 conference announcement for Avidity (RNA) include financial or clinical results?

No; the notice only announces the management panel and webcast availability without financial or clinical data.